3-Diarylmethylenes for PP2A-Mediated FOXO Reactivation in Resistant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate and triple-negative breast cancers are inadequate, as they often develop resistance to androgen deprivation therapy and chemotherapy, respectively, necessitating new therapies to target dysregulated FOXO and Myc pathways.
Innovation Solution
3-diarylmethyl cycloamine urea analogs modulate PP2A activity to induce FOXO1 and FOXO3 translocation, deactivating pro-growth kinases like phospho-ERK and phospho-AKT, offering anti-proliferative effects and restoring sensitivity to chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If androgen deprivation therapy is used to treat prostate cancer, then tumor growth is initially controlled, but tumors develop resistance and progress to castration-resistant prostate cancer
Solution Approach 1:
The patent changes the therapeutic parameter by targeting PP2A phosphatase activity instead of androgen receptors. The compound modulates PP2A to dephosphorylate and activate FOXO transcription factors, shifting the mechanism of action from androgen pathway inhibition to phosphatase-mediated FOXO activation, thereby overcoming androgen deprivation resistance
Solution Approach 2:
The patent introduces PP2A as an intermediary target between the drug compound and the cancer cells. The compound does not directly kill cancer cells but rather modulates PP2A activity, which then indirectly activates FOXO factors and triggers apoptosis, creating a multi-step therapeutic mechanism that overcomes direct androgen pathway resistance
2Reliability
If chemotherapy is used to treat triple-negative breast cancer, then tumor proliferation is initially reduced, but tumors develop resistance and become chemotherapy-resistant
Solution Approach 1:
The patent changes the therapeutic parameter by modulating PP2A phosphatase activity rather than using direct cytotoxic chemotherapy. The compound activates FOXO transcription factors through PP2A-mediated dephosphorylation, fundamentally altering the cellular response mechanism from chemotherapy-induced cell death to phosphatase-regulated apoptosis pathways, thereby overcoming chemoresistance
Solution Approach 2:
The patent achieves multi-functionality by having the PP2A modulator simultaneously activate multiple FOXO factors (FOXO1, FOXO3a, FOXO4, FOXO6) and regulate multiple downstream targets including BIM, Myc, and various signaling pathways (PI3K-AKT, MAPK, mTOR), creating a broad-spectrum anti-cancer effect that overcomes specific chemoresistance mechanisms
3Stability of the object's composition
If PP2A is inhibited to stabilize FOXO phosphorylation, then FOXO remains cytosolic and inactive, but cancer cells proliferate unchecked
Solution Approach 1:
The patent inverts the conventional PP2A inhibition approach by using PP2A activation/modulation. Instead of stabilizing FOXO phosphorylation through inhibition, the compound modulates PP2A to achieve appropriate dephosphorylation and nuclear translocation of FOXO factors, reversing the logic to achieve better cellular control and apoptosis
Data Source
AI summary
3-Diarylmethylenes are disclosed. The compounds activate PP2A, suppress oncogenic kinase signaling, and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.